(A) A flow chart depicting the stages from tumor biopsy to tumor cell sequencing, to neoantigen identification, to mRNA-based neoantigen vaccine administration. (B) Antibody immunotherapy activates a range of T cells in the body, with a low proportion of T cells specific to the cancer. (C) A neoantigen vaccine can stimulate the patient’s T cells to be optimally targeted against antigens specific to the cancer, and the addition of antibody immunotherapies to the neoantigen vaccine stimulates the response of T cells to attack the cancer.